carbamates and ticlopidine

carbamates has been researched along with ticlopidine in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sternon, J1
Jilma, B; Krumphuber, J; Siller-Matula, JM1
Backman, JT; Filppula, AM; Kailari, O; Neuvonen, M; Neuvonen, PJ; Niemi, M; Nyrönen, TH; Tapaninen, T; Tornio, A1

Reviews

2 review(s) available for carbamates and ticlopidine

ArticleYear
[New drugs].
    Revue medicale de Bruxelles, 2001, Volume: 22, Issue:4

    Topics: Amdinocillin; Carbamates; Clopidogrel; Cyclohexanes; Drug Interactions; Humans; Hypoglycemic Agents; Nateglinide; Patient Selection; Penicillins; Phenylalanine; Piperidines; Platelet Aggregation Inhibitors; Pneumococcal Vaccines; Raloxifene Hydrochloride; Safety; Selective Estrogen Receptor Modulators; Ticlopidine

2001
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.
    British journal of pharmacology, 2010, Feb-01, Volume: 159, Issue:3

    Topics: Adenosine; Adenosine Monophosphate; Benzofurans; Blood Platelets; Carbamates; Clinical Trials as Topic; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Receptor, PAR-1; Receptors, Proteinase-Activated; Thiophenes; Ticagrelor; Ticlopidine; von Willebrand Factor

2010

Trials

1 trial(s) available for carbamates and ticlopidine

ArticleYear
Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions.
    Clinical pharmacology and therapeutics, 2014, Volume: 96, Issue:4

    Topics: Aryl Hydrocarbon Hydroxylases; Carbamates; Catalytic Domain; Clopidogrel; Computer Simulation; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Drug Interactions; Female; Glucuronides; Humans; Hypoglycemic Agents; Male; Metabolic Detoxication, Phase II; Molecular Docking Simulation; Piperidines; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors

2014